Aurora Cannabis (ACB) EBITDA (2017 - 2026)

Aurora Cannabis (ACB) has reported EBITDA for 10 consecutive years, with $9.2 million the latest figure, recorded in Q1 2026.

• Quarterly EBITDA fell 34.36% year-over-year to $9.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $29.4 million (down 5.22% YoY) and the FY2026 annual result came in at -$33.8 million, down 182.62% from the prior year.
• EBITDA slipped to $9.2 million in Q1 2026 per ACB's latest filing, from $18.4 million in the prior quarter.
• Over the last five years, EBITDA for ACB reached as high as $19.4 million in Q4 2024 and fell as low as -$4.8 billion in Q2 2023.
• A 5-year average of -$302.3 million and a median of $167381.5 in 2022 frame the typical range for EBITDA.
• Annual changes were most pronounced in 2023 — EBITDA sank 10000.51% — and 2025, when it jumped 506.12%.
• Year by year, EBITDA stood at $1.1 million in 2022, then surged by 391.34% to $5.2 million in 2023, then jumped by 275.18% to $19.4 million in 2024, then retreated by 5.27% to $18.4 million in 2025, then tumbled by 49.77% to $9.2 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered $9.2 million, $18.4 million, and $2.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.